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Abstract
In disseminated intravascular coagulation (DIC) there is extensive
crosstalk between activation of inflammation and coagulation.
Endogenous anticoagulatory pathways are downregulated by
inflammation, thus decreasing the natural anti-inflammatory mecha-
nisms that these pathways possess. Supportive strategies aimed
at inhibiting activation of coagulation and inflammation may
theoretically be justified and have been found to be beneficial in
experimental and initial clinical studies. This review assembles the
available experimental and clinical data on biological mechanisms
of antithrombin in inflammatory coagulation activation. Preclinical
research has demonstrated partial interference of heparin –
administered even at low doses – with the therapeutic effects of
antithrombin, and has confirmed – at the level of cellular mecha-
nisms – a regulatory role for antithrombin in DIC. Against this
biological background, re-analyses of data from randomized
controlled trials of antithrombin in sepsis suggest that antithrombin
has the potential to be developed further as a therapeutic agent in
the treatment of DIC. Even though there is a lack of studies
employing satisfactory methodology, the results of investigations
conducted thus far into the mechanisms of action of antithrombin
allow one to infer that there is biological plausibility in the value of
this agent. Final assessment of the drug’s effectiveness, however,
must await the availability of positive, prospective, randomized and
placebo-controlled studies.
Introduction
Antithrombin is a vitamin K independent glycoprotein and an
essential inhibitor of thrombin and other serine proteases
such as factors Xa and IXa [1]. Acquired antithrombin
deficiency is more frequent than congenital deficiency and
develops primarily through increased consumption or loss of
antithrombin. The reduced plasma level in acquired deficiency
is a strong predictor of a severe disease course, particularly
in patients who have suffered trauma or severe sepsis.
Increased consumption of antithrombin occurs primarily in
disseminated intravascular coagulation (DIC) [2-8]. A
diagnosis of DIC is made after taking into consideration the
triggering disease, clinical picture, and unambiguous and
striking hemostatic findings such as a drop in thrombocytes,
loss of antithrombin activity, increased concentrations of D-
dimers or fibrin monomers [7].
Based on the assumed inhibition by antithrombin of activated
clotting factors in the circulating vascular system, concen-
trated human plasmatic antithrombin was administered in the
setting of DIC in isolated cases [2,4-6,8], in animal experi-
ments [6,9-13], and in clinical studies [14-18] with the aim of
interrupting the complex cycle of DIC and preventing multiple
organ failure. In these studies the duration of DIC was
significantly shortened and organ functions were improved,
but no significant reduction in mortality in the antithrombin
groups was achieved. Proof of reduced lethality from DIC
with administration of concentrated human plasmatic anti-
thrombin in prospective controlled clinical studies has not yet
been reported.
The largest number of patients with acquired antithrombin
deficiency treated with human plasmatic antithrombin in a
prospective controlled clinical study can be found in the
KyberSept trial [19]. Patients with severe sepsis were
recruited for this study independent of the cause or duration
of sepsis and irrespective of the presence or absence of DIC.
Therapeutic doses of heparin were not permitted because of
the interaction of this agent with antithrombin and its anti-
coagulatory effects. In prophylactic doses, however,
administration of heparin was permitted. Compared with
placebo, treatment with high-dose antithrombin over 4 days
had no significant effect on mortality at 28 days. Failure to
demonstrate effectiveness of antithrombin may be due to the
heterogeneity of the patient population investigated. Inter-
action between antithrombin and heparin was considered a
possible reason, because antithrombin achieved a significant
reduction in mortality at 90 days in a subgroup of patients who
did not simultaneously receive prophylactic doses of heparin.
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This review addresses the potential relevance of new
knowledge on the mechanisms of action of antithrombin to
the practising clinician.
Characteristics of antithrombin
The two basic endogenous anticoagulation principles that
have an inhibitory effect on the coagulation cascade are the
heparin–antithrombin and the protein C thrombomodulating
mechanisms. Both of these inhibit serine proteases and
cofactors/activated coagulation factors [1].
Antithrombin is a 58 kDa glycoprotein that is composed of a
single amino acid chain with a plasma concentration of about
150–150 µg/ml (2–3 µmol/l). The total 432 amino acids
carry four N glycosylated oligosaccharide chains and three
disulfide bridges. In the presence of heparin, antithrombin
strongly inhibits not only thrombin and factor Xa but also
factor IXa, and it weakly inhibits factors XIa and XIIa, trypsin,
plasmin, kallikrein and factor VIIa [15-17,20,21]. This broad
spectrum of inhibition makes antithrombin the key regulator of
the coagulation system. In addition, antithrombin appears to
have anti-inflammatory properties that appear to be distinct in
their mechanism from this effect on coagulation that is
dependent on enzyme inhibition.
Two isoforms of antithrombin circulate in the plasma, namely
the α and the β forms, which do not differ from each other in
their thrombin inhibiting effect, but they differ in their affinity
for heparin. Under normal conditions, 85–95% of circulating
antithrombins are glycosylated at four of their asparagine
molecules; these are of the α isoform. The remaining 5–15%
of circulating antithrombins, of the β isoform, lack glycosy-
lation at asparagine 135, which results in their 3- to 10-fold
greater affinity for heparin [22].
Anticoagulation
Heparin exerts an anticoagulatory effect by binding to
antithrombin and thereby alters its conformation in such a
manner that it inhibits thrombin 1000-fold more strongly [23].
It builds up a stoichiometric complex with thrombin, at a 1:1
ratio, over a reactive arginine-containing loop and a catalytic
serine-containing interaction site. As soon as a thrombin–
antithrombin (TAT) complex is formed, both molecules are
inactivated (Fig. 1). The TAT complex has a short plasma half-
life of only 5 min and is disposed of by its binding to the so-
called low-density lipoprotein receptor-related protein of the
liver [24,25].
In order for thrombin to be inactivated by antithrombin, not
only must heparin be bound to antithrombin but it must also
accumulate on thrombin. Nonfractionated, high-molecular-
weight heparins, which have several pentasaccharide
sequences, can thus promote the antithrombin-dependent
inactivation of thrombin. This bivalent interaction does not
require the presence of antithrombin to inhibit other serine
proteases, such as factor Xa or the contact factors. This
explains why, compared with the other factors, thrombin is
inhibited more weakly by low-molecular-weight heparins.
Proteoglycans, such as heparan sulfate proteoglycans
(HSPGs), are expressed on the surface of vessel endo-
thelium. It has been estimated that there are about 500,000
binding sites for antithrombin on each single endothelial cell
on the inner surface of the blood vessels [26]. If the heparin-
binding capacity of circulating antithrombin is not blocked or
exhausted by soluble heparin or by HSPG detached from the
endothelium, the deposition of antithrombin on surface
heparins of the endothelium can help antagonize the
activated thrombin also deposited at the same sites of the
endothelium in vessel injury [26]. This mechanism might be of
significance in the maintenance of microcirculation.
Anti-inflammation
The anticoagulatory properties of antithrombin have been
investigated relatively exhaustively and have been known for
some time for their inhibitory effect on serine proteases.
Since the late 1980s, additional results from several
laboratories have shown that antithrombin also has strong
anti-inflammatory properties that are independent of its
anticoagulatory characteristics. These effects were first
postulated by Taylor and coworkers [27,28] based on their
experiments on DIC in a monkey model. Infusions of
antithrombin significantly reduced mortality in monkeys
previously treated intravenously with lethal doses of
Escherichia coli. The therapeutic effects on systemic blood
pressure and organ failure, however, could not be explained
on the basis of its direct effect on thrombin. These
observations were supported by the fact that DEGR–factor
Xa, a catalytically inactive factor Xa derivative that selectively
Figure 1
Interaction of antithrombin with endothelium. The affinity of
antithrombin (AT) to thrombin and its enzymatic inhibition is increased
by binding of AT with the heparan-binding site to cellular heparin
sulfate proteoglycans (HSPGs). TAT, thrombin–antithrombin.Page 3 of 9
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blocks production of thrombin, also had no influence on
organ failure in this model.
An early explanation for this anti-inflammatory effect of anti-
thrombin presented itself when it was shown that antithrom-
bin promotes the release of prostacyclin (prostaglandin I2)
from the endothelium, which – both in vitro and in vivo – can
interact with heparin-like glycosaminoglycans of the endo-
thelium surface [29-31] (Fig. 2).
Endotoxin-induced damage to pulmonary blood vessels [32]
as well as hepatic ischaemia/reperfusion lesions [31] can be
decreased with antithrombin via induction of endothelial
prostaglandin production. The protective effect could not be
achieved with Trp49–antithrombin (a modified antithrombin)
because, lacking affinity to heparin, it was unable to induce
release of endothelial prostacyclin. In independent investi-
gations conducted in a mesenteric ischaemia/reperfusion
feline model, Ostrovsky and coworkers [33] showed that anti-
thrombin exerts its protective effect by inhibiting rolling and
adhesion of leucocytes on the endothelium. Hoffmann and
coworkers [34] and Neviere and colleagues [35] later con-
firmed this effect in a rat model by intravital videomicroscopy
of damage to the small intestine in endotoxinaemia. In both of
these studies, the effect of antithrombin on the leucocyte–
endothelium interaction could be abolished by indomethacin,
which is an inhibitor of prostacyclin production. HSPGs
(heparin-like glycosaminoglycans) are involved as mediators
in the effect of antithrombin on the leucocyte–endothelium
interaction. There are indications that syndecan-4 (an HSPG
member of the syndecan family) mediates, as one of the
antithrombin receptors on endothelial cells, these direct
effects of antithrombin [36-38]. Antithrombin reduced the
ischaemia/reperfusion induced renal or hepatic injury by
inhibiting leucocyte activation, suggesting that therapeutic
effects of antithrombin might be mainly mediated by
prostacyclin released from endothelial cells through inter-
action of antithrombin with cell surface glycosaminoglycans
[39,40]. Organ systems protected by antithrombin in ischaemia/
reperfusion via such mechanisms may include those of the
central nervous system [41,42].
Syndecan-4 is expressed by leucocytes, and moreover anti-
thrombin can regulate the migratory behaviour on the cell
surface of neutrophils, monocytes, lymphocytes and eosino-
philes [36,38,43]. In its highly conserved heparin sulfate
ectodomains, syndecan-4 possesses pentasaccharide arrays
that are recognized by the heparin-binding site of the
antithrombin molecule [30,44]. With reagents such as
heparinase or natrium chlorate that degrade heparin sulfate,
the effect of antithrombin on leucocyte migration could be
abolished [36-38,43]. In agreement with this is the
observation that syndecan-4 deficiency in knockout mice
increases mortality in endotoxinaemia [45]. Even the smallest
doses of heparin such as those used in thrombosis prophy-
laxis can have a negative impact on the beneficial effect of
antithrombin on microcirculatory disturbances in endo-
toxinaemia [46]. This might be due to the fact that heparin
competitively inhibits the binding of antithrombin to syndecan-
4 or other HSPGs. It has been reported in human umbilical
cord endothelial cells that, under static conditions,
antithrombin inhibits endotoxin or cytokine induced signaling
and adherence of neutrophils [47] (Fig. 2). Coincubation of
antithrombin with a synthetic exogenous pentasaccharide or
pretreatment of endothelial cells with heparinase or
chondroitinase abolished the effect of antithrombin on
neutrophil adherence. Based on these observations it was
concluded that antithrombin has the capacity to block
endothelial cell activation via activation of syndecan-4-
dependent signal transduction.
In their investigations into the intracellular mechanisms that
underlie the anti-inflammatory effects of antithrombin,
Oelschläger and coworkers [48] confirmed that antithrombin
inhibits activation of nuclear factor-κB (NF-κB) in cultured
human monocytes and endothelial cells [49]. The trans-
cription factor NF-κB activates various genes that encode
immune factors in reactions to inflammatory stimuli [50]. That
this mechanism is inhibited with antithrombin represents a
plausible explanation for the anti-inflammatory effects
described. This inhibition of NF-κB was observed in an in
vitro concentration of antithrombin corresponding to its level
in the plasma, a concentration required for therapeutic anti-
inflammation  in vivo [51] or for other effects described in
vitro [52].
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Figure 2
Inflammation-modulating effect of antithrombin on the endothelium.
Ligation of heparan sulfate proteoglycans (HSPGs) of endothelium
with antithrombin (AT) induces cellular signalling events that alter the
cell’s biochemical and functional responses to inflammatory stimuli (e.g.
bacterial lipopolysaccharide [LPS]). Changes include reduced release
of inflammatory and procoagulatory mediators (e.g. interleukin [IL]-1,
IL-6, tumour necrosis factor-α [TNF]), tissue factor (TF), adenosine
diphosphate (ADP) and cellular adhesion molecules (not shown), as
well as increased release of anticoagulatory prostacyclin (prostaglandin
[PG]I) or CD39/ATPDase. In neuronal tissue, protective mechanisms
may by mediated via the release of calcitonin gene-related peptide and
nitric oxide with the potential to affect prostacyclin release [55].Additional  in vitro findings on inhibition of β2 integrin
expression in neutrophils and monocytes by antithrombin [53]
suggest that direct molecular mechanisms underlie inhibition
of leucocyte adhesion to the endothelium. Antithrombin
inhibited the tumour necrosis factor (TNF)-α induced increase
in E-selectin expression in endothelial cells by inhibiting the
interaction of NF-κB with CBP/p300 through cAMP-depen-
dent protein kinase A-induced CREB activation [54]. This
inhibitory activity of antithrombin probably also depends on its
binding to heparin-like substances on the endothelial cell.
Because of the widespread expression of HSPGs, sites of
action for antithrombin may not be restricted to endothelium
and leucocytes but may well include additional targets.
Evidence for this came from studies in ischaemic/reperfusion
injury of the liver; antithrombin might increase hepatic tissue
levels of prostacyclin via enhancement of hepatic injury
induced activation of capsaicin-sensitive sensory neurones,
thereby reducing liver injury in rats. In this process, calcitonin
gene-related peptide-induced activation of both endothelial
nitric oxide synthase and cyclo-oxygenase-1 might be
critically involved [55]. Because in such a scenario the site of
action of antithrombin is within the interstitium, prior
extravasation of circulating antithrombin would have to be a
prerequisite for anti-inflammatory activity to be exerted. Of
course, this also has implications for estimating dose–
response relationships because it will be difficult to determine
extravascular concentrations of antithrombin.
Interaction between antithrombin and heparin
It is clear that antithrombin has anti-inflammatory properties in
addition to its anticoagulation ones. Because the anti-
inflammatory effects are exerted via interaction between
antithrombin and its heparin-binding domains and the
heparin-like receptors on the surfaces of endothelial cells and
leucocytes such as HSPG syndecan-4, it is not surprising
that the antithrombin concentrations required for this differ
from those for anticoagulation and lie in ‘supraphysiological’
region.  In vitro and in animal models, low doses of
unfractionated or low-molecular-weight heparin antagonized
this HSPG-mediated effect, because the binding of
antithrombin to the cellular HSPG was blocked by exogenous
heparin [46] (Fig. 3). It was previously shown antithrombin–
heparin treatment significantly attenuated the endotoxin-
induced consumption of fibrinogen and completely prevented
the increase in soluble fibrin in plasma; however, no
significant effect of antithrombin III–heparin was observed on
endotoxin-induced mortality and dysfunction in pulmonary gas
exchange. We therefore conclude that a purified antithrombin–
heparin complex inhibits thrombin effects and prevents
development of DIC, but it fails to influence clinical outcome
significantly in endotoxic shock in pig [56].
Therapy for severe sepsis, which in its initial phase is a
proinflammatory, life-threatening disease, with antithrombin
was evaluated in a randomized, controlled study (KyberSept)
conducted in 2314 patients [19]. Total mortality on day 28
after the start of therapy in patients in the intention-to-treat
group (who received antithrombin) was no different from that
in the placebo group (38.9% for antithrombin versus 38.7%
for placebo). This finding was counter to the raised expecta-
tions stimulated by phase II trials [14-18,21]. Concomitant
with the study medication, one subgroup of patients was
given heparin for thrombosis prophylaxis. Because, according
to subgroup analysis, antithrombin reduced 90-day mortality
only in the group of patients who did not receive heparin at
the same time, an interaction between antithrombin and
heparin was postulated that probably offset the beneficial
anti-inflammatory properties of the former [19,57,58].
Although prophylactic and therapeutic use of heparin in
venous thromobosis and pulmonary embolism has been
extensively investigated during the past 50 years, its employ-
ment in patients with sepsis has not yet been evaluated in
prospective studies. In small studies a beneficial effect of
heparin on survival of patients with sepsis could not be
demonstrated [59]. In the KyberSept study, administration of
prophylactic doses of heparin was permitted by the protocol
[19,57]. Because the possibility of an interaction with
antithrombin had not been excluded, the subgroup analysis
was determined a priori, before the start of the study,
although there was no stratification for heparin. Analyses of
heparin were carried out post hoc in Kybersept, which
distinguishes it from other retrospective calculations that
were justifiably the subject of criticism [60].
The post hoc analyses of the effectiveness of antithrombin in
severe sepsis without concomitant administration of heparin
[57] supported the hypothesis that prophylactic administra-
tion of heparin interferes with the therapeutic effect of
antithrombin. Although definitive statistical proof is lacking, it
is quite likely that the increasing loss of efficacy of anti-
thrombin over the time course of the KyberSept trial is
associated with increasing concomitant administration of
heparin [57]. In addition, the combination of antithrombin and
heparin led to a significant increase in bleeding complica-
tions, even though no increase in mortality was shown to
result from them. Conversely, antithrombin therapy without
heparin did not result in an increase in the number of severe
thromboembolic events, which would suggest that
withholding prophylactic heparin during antithrombin therapy
does not present any new safety problems [57].
Further, rather less direct confirmation of the role of heparin
as an unfavourable interaction partner with antithrombin in
severe sepsis comes from another predefined subgroup
analysis of the KyberSept trial. It was shown that, in
KyberSept, those patients who failed to derive any benefit
from antithrombin either were too ill to survive sepsis despite
optimal therapy (predicted mortality >60%) or were too well
to die in adequate numbers for the study conditions
(predicted mortality <30%). In the group of patients with the
Critical Care    Vol 10 No 1 Wiedermann
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30% and 60%), a statistically significant improvement in
survival to day 90 of the observation period was seen in the
antithrombin group, irrespective of whether the patients in
this group concomitantly received heparin; if those patients
who received heparin were excluded from the analysis, the
therapeutic effect of antithrombin was even stronger [61].
Results of preclinical research carried out after the KyberSept
study suggested the possibility of an undesirable drug
interaction between antithrombin and heparin, and this –
together with previous knowledge on this subject – provided
the justification for re-analyses of the findings. The data
support the assumption that if administration of heparin
concomitantly with antithrombin is withheld, then the anti-
inflammatory potential of the latter can be improved.
Disseminated intravascular coagulation and
antithrombin-dependent inhibition of
inflammation
DIC is a complex event both from diagnostic and from
therapeutic perspectives. DIC can be triggered by numerous
diseases that are quite independent from each other. It is not
a disease entity in its own right but manifests as a
consequence or complication of some severe underlying
disease. Activation of coagulation within the context of such
an underlying disease induces excessive intravascular
coagulation that can manifest in various ways. It can lead to
the formation and deposition of fibrin so that micro-
thromboses develop in multiple organs (Fig. 4). The extensive
and persisting activation of the coagulation system may also
result in reduced levels of coagulation factors. Consumption
of these factors is promoted by reduced synthesis in the liver,
and their shortened half-life is dependent on activation of
proteases. Consumption of coagulation factors and the
subsequent thrombocytopenia can lead to the development
of microthromboses and severe vascular complications.
DIC is among the most frequent complications of sepsis,
which is almost always associated with hemostatic changes.
Patients with septic shock who develop DIC exhibit higher
mortality rates than do those without signs of DIC. With its
ubiquitous microthrombosis, DIC plays an essential role in the
development of organ dysfunction in septic shock, such that
DIC can be considered a primary pathogenetic factor in multi-
organ failure. In sepsis, laboratory data demonstrate not only
changes in the number of leucocytes but also a reduction in
the number of thrombocytes and antithrombin concentration.
Inflammation-dependent activation of
coagulation
Increased levels of circulating cytokines follow a marked
increase in the markers for thrombin formation (prothrombin
fragments F1 and F2, and TAT complex) and for the
Available online http://ccforum.com/content/10/1/209
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Figure 3
Molecular mechanism underlying the interaction between antithrombin and heparin. Signalling events triggered by antithrombin (AT) affect
chemotaxis receptor function. Mediator release and adhesion molecule expression is altered by inhibiting the interaction of nuclear factor-κB
(NF-κB) with CBP/p300 through cAMP-dependent protein kinase A-induced CREB activation [54]. Exogenous unfractionated heparin or low-
molecular-weight heparin (LMWH) may prevent AT from interacting with heparin sulfate proteoglycans (HSPGs) by competitive ligand binding at
the heparin binding site of AT. PK, protein kinase; RANTES, regulated upon activation, normal T-cell expressed and secreted.conversion of fibrinogen to fibrin (fibrinopeptide A and fibrin
monomers) [62]. A similar activation of the coagulation
system can be observed when TNF is injected into individuals
[63]. Concomitant administration of pentoxifyllin and
endotoxin in chimpanzees blocked endotoxin-induced TNF
expression, and also inhibited activation of coagulation [64].
Thus, TNF is not only a central mediator in the cytokine
cascade but also must be viewed as a decisive mediator of
endotoxin-induced activation of the coagulation system.
Initial activation of the coagulation system in sepsis occurs
primarily via the extrinsic system; that is, it is dependent on
tissue factor (TF). In primates, infusions of high doses of E.
coli were followed by strong expression of TF [65]. Further-
more,  in vitro studies showed that endotoxin and cytokine
induced TF expression in monocytes and endothelial cells
[66]. TF binds to factor VIIa, resulting in a TF–factor VIIa
complex, which is responsible for the conversion of factor X
to factor Xa. In children with meningococcal sepsis, mono-
cytes exhibit increased TF expression [67]. One can assume
that the TF-dependent system plays a predominant role in
activation of coagulation in sepsis.
The coagulation system comprises several inhibitory systems
that are of great importance, with antithrombin and protein
C–protein S systems in the foreground. In sepsis, however,
reduced activity of inhibitory systems has been measured in
general [68]. This further contributes to the development of a
pro-coagulatory condition.
As a rule, the number of thrombocytes is reduced within the
context of a septic event. This reduction is explained by their
being used up in the region of fibrin deposits, by their
adhesion to altered endothelial cells, and by pulmonary and
hepatic sequestration. Generally speaking, there is a close
correlation between lowering of thrombocyte numbers and
mortality in patients. Disturbances in platelet function not only
result from sepsis but can also arise in the context of
antibiotic therapy, or they may be associated with sepsis-
dependent uraemia.
Effects of antithrombin on monocytes and
thrombocytes
Antithrombin binds to syndecan-4 in monocytes and
thrombocytes, activates various signal transduction pathways,
and thereby influences the functional behaviour of both of
these blood cell types, which are so important in DIC
[36,37,53,69]. Signal transduction enzymes that are involved
in monocytes in vitro include protein kinase C [37], Rho-GTP
associated kinases [38], src tyrosine kinases [69] and
sphingosine kinase [37].
Antithrombin enhances Tyr416 and inhibits Tyr527 phos-
phorylation of src tyrosine kinases; in combination with the
chemokine RANTES (regulated upon activation, normal T-cell
expressed and secreted); however, it weakens the RANTES-
enhanced phosphorylation of Tyr416 [69]. These effects of
antithrombin correspond to a large extent with the well known
syndecan-4 induced signalling pathways [70]. It can be
assumed that antithrombin is also able to exert specific anti-
coagulatory and anti-inflammatory effects in thrombocytes via
analogous biochemical mechanisms because it is known that
syndecan-4 is also expressed by thrombocytes and that anti-
syndecan-4 antibodies can influence thrombocyte aggregation
[71].
Antithrombin inhibits chemotaxis [36,37] and expression of
TF and cytokines [52] in monocytes. In activated
thrombocytes, antithrombin inhibits CD40 ligand expression,
syndecan-4 shedding, and release of adenosine diphosphate
and adenosine triphosphate, together with inhibition of
thrombocyte-regulated release of free radicals from
neutrophils [71]. Because all of these mechanisms play a role
in activating thrombocytes in DIC patients, it can be assumed
that antithrombin deficiency also contributes to the
development of DIC via such direct cellular mechanisms,
under the stipulation that the in vitro observations of
functional regulation of thrombocytes are confirmed in vivo.
The same applies for the possible relevance of direct
antithrombin effects on monocytes.
Antithrombin therapy in acquired disseminated
intravascular coagulation in sepsis
Post hoc analyses of the effectiveness of antithrombin in
severe sepsis without concomitant administration of heparin
supported the hypothesis of the KyberSept study that
prophylactic heparin interferes with the therapeutic effects of
antithrombin [57,61]. Because antithrombin therapy without
concomitant treatment with heparin was effective in the
KyberSept trial, it appeared reasonable to investigate the
Critical Care    Vol 10 No 1 Wiedermann
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Figure 4
Disseminated intravascular coagulation. Arrows indicate intravascular
fibrin deposition.same cohort of patients to find out whether the effectiveness
of such therapy was dependent on the presence of DIC.
Such an investigation was reported by Kienast and
coworkers [72]. A total of 563 patients who did not receive
heparin concomitantly with antithrombin were evaluated
(n = 277 for placebo; n = 286 for antithrombin). At the begin-
ning of therapy, 40.7% of the patients (229/563) had DIC. In
the placebo group DIC signified enhanced mortality due to
sepsis (28-day mortality: 40.0% versus 22.2%; P < 0.01).
DIC patients treated with antithrombin exhibited an absolute
reduction (14.6%) in 28-day mortality in comparison with
placebo-treated patients (P = 0.02); in contrast, no such
effects were noted among patients without DIC (0.1%
reduction in mortality; P = 1.0). These analyses in a
randomized study population confirmed that antithrombin
therapy can have a favourable influence not only on the
morbidity associated with severe sepsis but also on mortality
if, in addition to withholding concomitant administration of
heparin, substitution therapy is given, particularly to those
patients with acquired antithrombin deficiency in whom acute
DIC has been diagnosed [72].
Limitations
Experimental studies have shown that high doses of
antithrombin (>500 UI/kg body weight) elicit anti-inflam-
matory effects and most experimental studies used a high-
dose pretreatment protocol, which is of little clinical relevance
[2,10,11,13,27]. However, supranormal levels have not been
achieved in human trials because the highest dose regimens
could only induce 200–250% antithrombin activity. It is
therefore unknown whether anti-inflammatory effects of high-
dose antithrombin indeed play a clinical role in humans.
Timing of antithrombin administration in experimental and
clinical studies may be another critical determinant of
efficacy. Most experimental studies used a high-dose
pretreatment protocol, which is of little clinical relevance. On
the other hand, very early suppression of inflammation may
exert adverse effects on the initial response to injury. In
experimental acute lung injury induced by inhalation of Gram-
negative bacteria, simultaneous intravenous administration of
recombinant human antithrombin caused histologic damage,
injury to the alveolar capillary barrier and increased
permeability in rodents [73]. These effects of inhibition of
thrombin activation by antithrombin led to the hypothesis that
there is a beneficial role of early coagulation activation in
acute lung injury, and that inhibition of initial procoagulation is
potentially dangerous.
Furthermore, biologically, the effect of antithrombin may be
modified directly by bacterial endotoxins because porins
(nonspecific channels of the bacterial outer membrane that
allow transmembrane passage of nutrient molecules that are
usually small and hydrophilic) not only enhanced thrombin
activity but also inhibited the enhanced antithrombin activity
resulting from antithrombin administration [74]. The
mechanisms of such inhibitory interaction of porins with
antithrombin remain to be detailed; however, antithrombin’s
heparin-binding site may well be among the potential targets
because affinity of porins to heparin-binding domains of
matrix proteins was recently reported [75].
Finally, antithrombin may interfere with the cytotoxic effects of
lymphocytes via its serine protease-inhibitory (SERPIN)
action on granzymes, which are death-inducing proteases
stored in the granules of cytotoxic lymphocytes that allow the
immune system to eliminate intracellular pathogens and
transformed cells rapidly [76]. In severe sepsis, elevation of
granzyme plasma levels correlates with disease severity [77].
Whether this SERPIN activity of antithrombin is beneficial or
deleterious is unknown.
Conclusion
On one hand, antithrombin research conducted during the
past two decades has attempted to establish the
effectiveness and safety of antithrombin substitution in cases
of severe sepsis in accordance with the criteria of evidence-
based medicine. On the other hand, plausible mechanisms of
action of this drug were investigated in preclinical research to
assess its therapeutic use. KyberSept [19], the first large-
scale study conducted within the context of intensive care
medicine, investigated use of high-dose antithrombin in
severe sepsis, but it was unable to establish its effectiveness
because of the highly heterogeneous nature of the patient
population and a lack of clearly defined standard therapy
[78]. Results of preclinical research carried out
simultaneously, however, demonstrated partial interference of
heparin – administered even at low doses – with the
therapeutic effects of antithrombin. They also confirmed, at
the level of cellular mechanisms, the important role of
antithrombin in DIC. This knowledge provides a biological
background against which re-analyses of the results of the
KyberSept study appear to be justified; such analyses
suggest that antithrombin has the potential to be developed
further as a therapeutic agent in the treatment of DIC. Even
though there is a lack of studies employing satisfactory
methodology, the results of investigations conducted thus far
into the mechanisms of action of antithrombin allow one to
infer that there is biological plausibility in the value of this
agent [79,80]. Even though several new aspects regarding
the biological role of antithrombin and it pharmacodynamcis
have recently been discovered, knowledge is still incomplete.
Final assessment of the drug’s effectiveness must await the
availability of positive, prospective, randomized and placebo-
controlled studies.
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